Management of Skin and Soft Tissue Infection of Keloid Scar at Suprapubic Area
For an infected keloid scar in the suprapubic area, immediately search for and drain any abscess formation, then treat with 5-6 days of antibiotics active against streptococci and MRSA, while addressing the keloid as a potential foreign body trigger for recurrent infection.
Initial Assessment and Source Control
The suprapubic location and keloid scar create a unique clinical scenario that requires specific attention to local factors. A recurrent abscess at a site of previous scarring should prompt a search for local causes such as foreign material within the keloid tissue itself 1. The keloid represents abnormal collagen deposition that can harbor bacteria and act as a nidus for recurrent infection.
Determine if Purulent vs. Nonpurulent
If purulent (abscess, fluctuance, or drainage present): Perform incision and drainage as the primary intervention 1
If nonpurulent (diffuse erythema, warmth, tenderness without pus collection): This is cellulitis requiring antimicrobial therapy as primary treatment 1
Critical pitfall: Do not call surrounding inflammation "cellulitis" if there is a purulent collection—the correct terminology is "abscess with surrounding inflammation," and drainage is the primary treatment, not antibiotics alone 1.
Antibiotic Selection
The suprapubic location and presence of scar tissue warrant broader coverage than simple cellulitis:
For Purulent Infection (Abscess):
- Clindamycin 300-450 mg PO TID or trimethoprim-sulfamethoxazole DS 1-2 tablets PO BID for 5-7 days after drainage 2
- These agents cover MRSA, which is more likely in purulent infections 3, 2
For Nonpurulent Infection (Cellulitis):
Given the suprapubic location with surgical scar history, empiric coverage should include both streptococci and MRSA 1:
- First-line: Vancomycin IV (if hospitalized) or oral agents with MRSA coverage
- Outpatient option: Clindamycin 300-450 mg PO TID or doxycycline 100 mg PO BID
- Duration: 5-6 days, extending only if not improved 1, 3
The 2014 IDSA guidelines specifically recommend MRSA coverage for cellulitis associated with penetrating trauma or evidence of MRSA elsewhere 1, which applies to infected surgical scars.
Addressing the Keloid as a Risk Factor
The keloid itself may perpetuate recurrent infection and should be considered for definitive management:
- Culture any purulent material to guide targeted therapy 1
- Consider 5-day decolonization regimen if S. aureus is isolated: intranasal mupirocin twice daily, daily chlorhexidine washes, and daily decontamination of personal items 1
- Definitive consideration: Keloid excision may be necessary if infections recur, as the abnormal scar tissue acts like foreign material 1
Hospitalization Criteria
Admit if any of the following are present 1:
- Systemic inflammatory response syndrome (SIRS)
- Hemodynamic instability
- Altered mental status
- Concern for deeper or necrotizing infection
- Severe immunocompromise
- Poor adherence anticipated
For severe infections requiring hospitalization, vancomycin plus piperacillin-tazobactam or a carbapenem provides appropriate broad-spectrum coverage 1.
Follow-up and Prevention
- Reassess at 48-72 hours to ensure clinical improvement
- If no improvement by day 5, extend antibiotic duration and reconsider diagnosis 1
- For recurrent infections: Strongly consider keloid excision as definitive management, as the scar tissue functions as a foreign body 1
- Evaluate for diabetes or immunosuppression, which significantly increases risk of deep abscess formation in the suprapubic region 4
The combination of keloid scar and suprapubic location creates higher risk for both MRSA involvement and potential deep extension along tissue planes, making aggressive initial management with appropriate MRSA coverage essential.